- Home
- EWCZ vs PRQR Comparison
EWCZ vs PRQR Comparison
Compare EWCZ & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- PRQR
- Stock Information
- Founded
- EWCZ 2004
- PRQR 2012
- Country
- EWCZ United States
- PRQR Netherlands
- Employees
- EWCZ N/A
- PRQR N/A
- Industry
- EWCZ Package Goods/Cosmetics
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- PRQR Health Care
- Exchange
- EWCZ Nasdaq
- PRQR Nasdaq
- Market Cap
- EWCZ 248.8M
- PRQR 179.1M
- IPO Year
- EWCZ 2021
- PRQR 2014
- Fundamental
- Price
- EWCZ $5.80
- PRQR $2.20
- Analyst Decision
- EWCZ Buy
- PRQR Strong Buy
- Analyst Count
- EWCZ 7
- PRQR 8
- Target Price
- EWCZ $5.86
- PRQR $8.88
- AVG Volume (30 Days)
- EWCZ 629.9K
- PRQR 371.0K
- Earning Date
- EWCZ 08-13-2025
- PRQR 08-07-2025
- Dividend Yield
- EWCZ N/A
- PRQR N/A
- EPS Growth
- EWCZ N/A
- PRQR N/A
- EPS
- EWCZ 0.21
- PRQR N/A
- Revenue
- EWCZ $216,469,000.00
- PRQR $21,212,711.00
- Revenue This Year
- EWCZ N/A
- PRQR N/A
- Revenue Next Year
- EWCZ $2.17
- PRQR N/A
- P/E Ratio
- EWCZ $28.25
- PRQR N/A
- Revenue Growth
- EWCZ N/A
- PRQR 85.91
- 52 Week Low
- EWCZ $2.72
- PRQR $1.07
- 52 Week High
- EWCZ $10.39
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- EWCZ 57.82
- PRQR 65.20
- Support Level
- EWCZ $5.48
- PRQR $1.89
- Resistance Level
- EWCZ $5.84
- PRQR $2.54
- Average True Range (ATR)
- EWCZ 0.27
- PRQR 0.13
- MACD
- EWCZ -0.06
- PRQR 0.01
- Stochastic Oscillator
- EWCZ 63.79
- PRQR 39.85
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.